read more

first_img Related Content January 25, 2012 — InSightec Ltd. announced that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its ExAblate treatment of pain palliation of bone metastases. ExAblate uses magnetic resonance guided focused ultrasound (MRgFUS) to treat the pain caused by bone metastases non-invasively and without ionizing radiation.Over 60 percent of cancer patients suffer from painful bone metastases. Of these, 30 percent will not respond to radiation therapy. ExAblate was investigated as an option for these patients. The PMA submission was based on a two-arm randomized controlled trial comparing patients undergoing ExAblate’s MR guided focused ultrasound for palliation of painful bone metastases with patients undergoing no treatment.Patients who had no response to the sham treatment were later allowed to undergo an ExAblate treatment. The FDA also granted an expedited review process for the PMA submission.ExAblate combines high intensity focused ultrasound to thermally ablate tumors and continuous MRI to visualize the anatomy, plan treatment and monitor treatment outcomes in real time.ExAblate is the only MRgFUS system with FDA approval, granted in 2004 for uterine fibroids. It also received European CE marking for uterine fibroids, bone metastases, and adenomyosis. Clinical trials are ongoing for brain disorders, including essential tremor and Parkinson’s disease, and prostate cancer.For more information: www.insightec.com, www.bone-pain-palliation.co.uk/ FacebookTwitterLinkedInPrint分享 News | Patient Positioning Radiation Therapy | August 07, 2019 Qfix kVue One Proton Couch Top Validated by Mevion Medical Systems Qfix and Mevion Medical Systems announced that a special version of the kVue One Proton couch top is now both validated… read more Technology | Interventional Radiology | August 16, 2019 Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to… read more News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more News | Radiation Therapy | August 15, 2019 First Patient Enrolled in World’s Largest Brain Cancer Clinical Trial Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive… read more Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al. News | Radiation Therapy | August 16, 2019 Drug Accelerates Blood System’s Recovery After Radiation, Chemotherapy A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem… read more News | Proton Therapy | August 08, 2019 MD Anderson to Expand Proton Therapy Center The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a… read more News | Patient Positioning Radiation Therapy | August 15, 2019 Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton… read more News | Neuro Imaging | August 16, 2019 ADHD Medication May Affect Brain Development in Children A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s… read more News | January 25, 2012 InSightec Seeks FDA Approval of MR-Guided Ultrasound to Treat Painful Bone Metastases Technology | Neuro Imaging | August 07, 2019 Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release… read more News | Magnetic Resonance Imaging (MRI) | August 06, 2019 Canon Medical Introduces Encore Orian MR Upgrade Program Canon Medical Systems USA Inc. is helping to provide low-cost patient care solutions for its customers with the launch… read more The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec. Catalyst PT image courtesy of C-RAD Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communicationslast_img

Leave a Reply

Your email address will not be published. Required fields are marked *